Cue Biopharma Inc Ret. on equity
What is the Ret. on equity of Cue Biopharma Inc?
The Ret. on equity of Cue Biopharma Inc is -142.93%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Cue Biopharma Inc
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Companies with ret. on equity similar to Cue Biopharma Inc
- Lyra Therapeutics has Ret. on equity of -143.74%
- Sihayo Gold has Ret. on equity of -143.40%
- Fortress Biotech Inc has Ret. on equity of -143.38%
- China Ruifeng Renewable has Ret. on equity of -143.25%
- Equitorial Exploration has Ret. on equity of -143.22%
- Pci Pal Plc has Ret. on equity of -143.07%
- Cue Biopharma Inc has Ret. on equity of -142.93%
- Canadian Overseas Petroleum has Ret. on equity of -142.83%
- Stavely Minerals has Ret. on equity of -142.82%
- Phio Pharmaceuticals has Ret. on equity of -142.68%
- Allakos Inc has Ret. on equity of -142.60%
- Nektar Therapeutics has Ret. on equity of -142.59%
- Accent Resources NL has Ret. on equity of -142.56%